SLC7A11 and neoplasm: Tumor cells with SLC7A11 knockdown exhibit higher vulnerability towards TMZ treatment and SLC7A11 inhibitors such as erastin and sorafenib potentiate a toxic impact of TMZ by induction of ferroptosis [86].